News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

News|Videos|August 1, 2024

Generics and Biosimilars in Multiple Sclerosis

Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.

Episodes in this series

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

Generics or biosimilar versions of many MS treatments are now available.
- How has this changed access to MS treatment for patients?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Linking Plasma p-tau217 to Brain Metabolism in Alzheimer Disease: Insights With Ana C. Pereira, MD

FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis

FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway

Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade

From Diagnosis to Treatment: Key Questions in Immune-Mediated Small Fiber Neuropathy